VivoSim Labs, Inc.
VIVSHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeVivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. At a $3.7M market cap, VivoSim Labs, Inc. ranks as a micro-cap company within healthcare. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Market Cap
$3.7M
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-4.46
EPS (Fwd)
—
ROE
-343.1%
ROA
-89.5%
Cash
$1.7M
Total Debt
$316,000
Free CF
-$7.6M
52W Change
-88.8%
Annual Financials
Cash vs Debt
Where VIVS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VIVS finished 77.78% below its 150-day moving average ($1.26) and 80.82% below its 200-day moving average ($1.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VIVS overbought or oversold?
At the September 3, 2026 close, VIVS's RSI(14) was 14.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
VivoSim Labs, Inc. holds $1.7M in cash against $316K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$7.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -343.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $370K (2023) to $131K (2026), a 65% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VIVS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.